The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment

Summary

A Randomized Clinical Trial that will compare the effects of Cannabidiol and Homotaurine in cognition and mental health in patients with Mild Cognitive Impairment and APOE ε4 carriers. Ninety patients will be recruited and they will be randomly distributed in three groups. The first group will receive treatment with Cannabidiol 5%, the second group will receive treatment with Vivimind and the third group will not receive any treatment. The three groups will be compared by using an extensive neuropsychological examination and biomarkers' results from cerebrospinal fluid and blood

Timeline

Start

2021-04-01

Primary completion

2022-12-20

Completion

2022-12-20

Drugs

Indications